Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Miragen Therapeutics stock | $18.03

Own Miragen Therapeutics stock in just a few minutes.

Fact checked

Miragen Therapeutics, Inc is a biotechnology business based in the US. Miragen Therapeutics shares (MGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Miragen Therapeutics employs 45 staff and has a trailing 12-month revenue of around USD$1.9 million.

How to buy shares in Miragen Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Miragen Therapeutics. Find the stock by name or ticker symbol: MGEN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Miragen Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$18.03, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Miragen Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Miragen Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Miragen Therapeutics share price

Use our graph to track the performance of MGEN stocks over time.

Miragen Therapeutics shares at a glance

Information last updated 2020-12-07.
Latest market closeUSD$18.03
52-week rangeUSD$4.665 - USD$34.05
50-day moving average USD$15.4053
200-day moving average USD$14.5705
Wall St. target priceUSD$40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.291

Buy Miragen Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Miragen Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Miragen Therapeutics price performance over time

Historical closes compared with the close of $18.03 from 2020-12-09

1 week (2021-01-11) -17.78%
1 month (2020-12-18) -9.62%
3 months (2020-10-16) 3,178.18%
6 months (2020-07-17) 1,600.94%
1 year (2020-01-17) 2,631.82%
2 years (2019-01-18) 497.02%
3 years (2018-01-18) 127.65%
5 years (2016-01-15) 2,673.85%

Miragen Therapeutics financials

Revenue TTM USD$1.9 million
Gross profit TTM USD$-28,633,000
Return on assets TTM -48.09%
Return on equity TTM -136.12%
Profit margin 0%
Book value $5.53
Market capitalisation USD$65.4 million

TTM: trailing 12 months

Shorting Miragen Therapeutics shares

There are currently 152,113 Miragen Therapeutics shares held short by investors – that's known as Miragen Therapeutics's "short interest". This figure is 63.2% down from 413,381 last month.

There are a few different ways that this level of interest in shorting Miragen Therapeutics shares can be evaluated.

Miragen Therapeutics's "short interest ratio" (SIR)

Miragen Therapeutics's "short interest ratio" (SIR) is the quantity of Miragen Therapeutics shares currently shorted divided by the average quantity of Miragen Therapeutics shares traded daily (recently around 1.0 million). Miragen Therapeutics's SIR currently stands at 0.15. In other words for every 100,000 Miragen Therapeutics shares traded daily on the market, roughly 150 shares are currently held short.

However Miragen Therapeutics's short interest can also be evaluated against the total number of Miragen Therapeutics shares, or, against the total number of tradable Miragen Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Miragen Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Miragen Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0391% of the tradable shares (for every 100,000 tradable Miragen Therapeutics shares, roughly 39 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Miragen Therapeutics.

Find out more about how you can short Miragen Therapeutics stock.

Miragen Therapeutics share dividends

We're not expecting Miragen Therapeutics to pay a dividend over the next 12 months.

Have Miragen Therapeutics's shares ever split?

Miragen Therapeutics's shares were split on a 1:15 basis on 13 November 2020. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Miragen Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Miragen Therapeutics shares which in turn could have impacted Miragen Therapeutics's share price.

Miragen Therapeutics share price volatility

Over the last 12 months, Miragen Therapeutics's shares have ranged in value from as little as $4.665 up to $34.05. A popular way to gauge a stock's volatility is its "beta".

MGEN.US volatility(beta: 1.35)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Miragen Therapeutics's is 1.349. This would suggest that Miragen Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Miragen Therapeutics overview

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site